Eledon Pharmaceuticals, Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; filed March 30, 2023. Eledon is a clinical-stage biopharmaceutical company developing tegoprubart, an anti-CD40L antibody. It had no approved products and generated no product revenue.
Key financial metrics
| Metric | FY 2022 / Dec. 31, 2022 | FY 2021 / Dec. 31, 2021 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $27.1 million | $23.7 million |
| General and administrative expense | $12.7 million | $13.1 million |
| Goodwill impairment | $48.6 million | None |
| Net loss | $88.0 million | $34.5 million |
| Net loss per share, basic and diluted | $6.16 | $2.33 |
| Net cash used in operating activities | $28.4 million | $28.9 million |
| Cash and cash equivalents | $56.4 million | $84.8 million |
| Working capital | $53.0 million | Not stated here |
| Total liabilities | $8.6 million | $6.6 million |
Gross margin and operating margin are not meaningful because the company had no product sales. The filing reports no credit facility or committed capital source; balance-sheet liabilities were primarily payables, accrued expenses, lease liabilities and a deferred tax liability.
Material changes and business developments
- Net loss increased by $53.5 million year over year, principally due to the $48.6 million non-cash goodwill impairment. The impairment followed a sustained decline in market capitalization and reduced goodwill to zero.
- R&D expense rose $3.3 million, reflecting higher clinical-trial, personnel and manufacturing costs. G&A expense decreased $0.4 million.
- Cash declined $28.4 million during 2022, broadly in line with operating cash use; there was no financing cash flow in 2022.
- In January 2023, Eledon announced it would prioritize kidney-transplant programs, discontinue islet-cell transplant development, and deprioritize IgA nephropathy (IgAN). It said it remained interested in advancing ALS development, but could not continue it without additional financing.
Outlook, risks and contingencies
- Management estimated that cash on hand would fund planned operating expenses into the first quarter of 2024. The company stated that additional financing is needed and that substantial doubt exists about its ability to continue as a going concern. The auditor’s report includes a going-concern explanatory paragraph.
- The planned Phase 2 kidney-transplant trial was expected to begin enrollment in the third quarter of 2023, subject to financing. The Phase 1b kidney-transplant study had dosed its first subject in July 2022.
- The Phase 2a ALS study met its primary safety and tolerability endpoints in topline results reported in May 2022: 50 of 54 participants completed six infusions, and no drug-related serious adverse events were reported. These findings do not establish efficacy; further development depends on financing.
- In January 2023, Eledon entered a research agreement with eGenesis for preclinical xenotransplantation studies. Payment is based on tegoprubart supplies needed for the studies.
- Liquidity risks include dependence on external financing, possible dilution or unfavorable financing terms, and cash balances above FDIC insurance limits. At the time of the March 2023 Silicon Valley Bank failure, approximately 78% of company cash was held there; the filing said the successor bank guaranteed access to deposits and Eledon was diversifying deposits.
- Other key risks include early-stage clinical and regulatory uncertainty, competition, reliance on third-party manufacturers and CROs, intellectual-property exposure, and potential clinical-trial delays. The filing reports no material legal proceedings or accrued contingencies.
Most important facts for investors to verify
- Current cash, cash burn and financing runway, including whether new capital or a partnership has been secured since the filing.
- Funding and actual enrollment timing for the kidney-transplant Phase 2 trial, and the status of the Phase 1b study.
- Whether and how ALS development will proceed, and what evidence supports efficacy beyond the reported safety and biomarker findings.
- Execution and economics of the eGenesis collaboration, and the implications of stopping islet-cell development and deprioritizing IgAN.
- Potential dilution: at year-end 2022, 1.15 million warrants were exercisable for common shares and preferred-stock warrants were convertible into approximately 2.79 million common shares; the company also had 5.22 million options outstanding.
- Exposure to uninsured bank deposits and the availability of ATM equity issuance: no ATM shares were sold in 2022, and the filing said the then-applicable baby-shelf limit permitted up to $10.5 million in sales.